PROTHENA CORP PLC (PRTA)
IE00B91XRN20 - Common Stock
PROTHENA CORP PLC
NASDAQ:PRTA (4/19/2024, 11:31:56 AM)
20.845
+0.27 (+1.34%)
Company Profile
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Company Info
PROTHENA CORP PLC
77 Sir John Rogersons Quay, Block C, Grand Canal Docklands
DUBLIN D02 VK60
P: 35312362500
CEO: Gene G. Kinney
Employees: 127
Website: https://www.prothena.com/
PRTA News
4 days ago - Prothena Corporation plcProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
22 days ago - Investor's Business DailyRace To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's SetbackThe FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
a month ago - Prothena Corporation plcProthena to Participate in Upcoming Healthcare Conferences
2 months ago - Prothena Corporation plcProthena Appoints David Ford to Newly Created Chief People Officer Position
2 months ago - Seeking AlphaProthena files to offer ordinary shares (NASDAQ:PRTA)Prothena files prospectus for offering of ordinary shares without disclosing the amount. This is not an offer to sell securities.
2 months ago - Seeking AlphaProthena appoints Daniel G. Welch as Chair Designate (NASDAQ:PRTA)Prothena Corporation appoints Daniel G. Welch as an independent director and Chair Designate, with plans to elect him as Chair of the Board later this year.
PRTA Twits
Here you can normally see the latest stock twits on PRTA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
